CSF2 and prostate carcinoma: It is the only approved dendritic cell vaccine that uses the patient’s own cells, re-engineered to overexpress prostatic acid phosphatase (PAP), an antigen on prostate cancer cells, and an immune stimulating cytokine, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF).